Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML Cooperative Group.
Major chemotherapeutic alternatives for AML have been implemented and compared in three multicenter studies, including a total of 877 adult patients of all ages. The results strongly suggest that myelosuppressive postinduction treatment is a prerequisite for the achievement of long-term remissions. In addition, it was possible to establish an important antileukemic effect of monthly maintenance chemotherapy. Initial results from an intensive two-course preremission therapy concept revealed good practicability and acceptable toxicity, as well as promising response and remission durations by this new approach.
Büchner
T
T
Hiddemann
W
W
Urbanitz
D
D
Kreutzmann
H
H
Maschmeyer
G
G
Wendt
F
F
Kuse
R
R
Mohr
A
A
Gassmann
W
W
Löffler
H
H
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005860:Germany, West; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008942:Mitoxantrone / Q000008:administration & dosage; D011897:Random Allocation; D012074:Remission Induction; D013866:Thioguanine / Q000008:administration & dosage
D003561:Cytarabine; D008942:Mitoxantrone; D013866:Thioguanine; D003630:Daunorubicin